This suggests that promoter usage (both for IGF2 and other cancer-driving genes) is cancer-type-specific and/or it may reflect the specific tumorigenic stage (specifically, early/partially differentiated versus advanced/fully dedifferentiated). Here, IGF2 is linked to cancer.